Label: FLAVOXATE HYDROCHLORIDE tablet, film coated
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Updated July 24, 2014
If you are a consumer or patient please visit this version.
- SPL UNCLASSIFIED SECTION
Flavoxate HCl tablets contain flavoxate hydrochloride, a synthetic urinary tract spasmolytic.
Chemically, flavoxate hydrochloride is 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4 -1-benzopyran-8-carboxylate hydrochloride. The empirical formula of flavoxate hydrochloride is C H NO •HCl. The molecular weight is 427.94. The structural formula appears below: H24254
Flavoxate HCl is supplied in tablets for oral administration. Each round, white, film-coated Flavoxate HCl tablet is debossed "PAD" and "0115" on one side and plain on the other side and contains flavoxate hydrochloride, 100 mg. Inactive ingredients consist of colloidal silicon dioxide, ethyl acrylate, hypromellose, lactose monohydrate, magnesium stearate, methyl methacrylate, microcrystalline cellulose, nonoxynol 100 and sodium starch glycolate. Film coating is composed of hypromellose 2910 6cP and polyethylene glycol.
Flavoxate hydrochloride counteracts smooth muscle spasm of the urinary tract and exerts its effect directly on the muscle.
In a single study of 11 normal male subjects, the time to onset of action was 55 minutes. The peak effect was observed at 112 minutes. 57% of the flavoxate HCl was excreted in the urine within 24 hours.
INDICATIONS AND USAGE
Flavoxate HCl tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate HCl tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.
Information for Patients:
Patients should be informed that if drowsiness and blurred vision occur, they should not operate a motor vehicle or machinery or participate in activities where alertness is required.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of flavoxate HCl have not been performed.
Teratogenic Effects–Pregnancy Category B.
Reproduction studies have been performed in rats and rabbits at doses up to 34 times the human dose and revealed no evidence of impaired fertility or harm to the fetus due to flavoxate HCl. There are, however, no well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when flavoxate HCl is administered to a nursing woman.
The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.
Nausea, vomiting, dry mouth. Gastrointestinal:
Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness. CNS:
Leukopenia (one case which was reversible upon discontinuation of the drug). Hematologic:
Tachycardia and palpitation. Cardiovascular:
Urticaria and other dermatoses, eosinophilia and hyperpyrexia. Allergic:
Increased ocular tension, blurred vision, disturbance in eye accommodation. Ophthalmic:
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- SPL UNCLASSIFIED SECTION
- Flavoxate HCL 100 MG TAB
INGREDIENTS AND APPEARANCE
flavoxate hydrochloride tablet, film coated
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68151-3826(NDC:0574-0115) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength FLAVOXATE HYDROCHLORIDE (UNII: 9C05J6089W) (FLAVOXATE - UNII:3E74Y80MEY) FLAVOXATE HYDROCHLORIDE 100 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) ETHYL ACRYLATE (UNII: 71E6178C9T) HYPROMELLOSES (UNII: 3NXW29V3WO) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) METHYL METHACRYLATE (UNII: 196OC77688) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) NONOXYNOL-100 (UNII: A906T4D368) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6) POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A) Product Characteristics Color WHITE Score no score Shape ROUND Size 11mm Flavor Imprint Code PAD;0115 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:68151-3826-0 1 in 1 PACKAGE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA076831 12/22/2004 Labeler - Carilion Materials Management (079239644) Registrant - Carilion Materials Management (079239644) Establishment Name Address ID/FEI Business Operations Carilion Materials Management 079239644 REPACK(68151-3826)